Phio Pharmaceuticals Corp. (PHIO)

NASDAQ: PHIO · IEX Real-Time Price · USD
0.726
-0.004 (-0.53%)
At close: Mar 27, 2024, 4:00 PM
0.710
-0.016 (-2.22%)
Pre-market: Mar 28, 2024, 4:00 AM EDT

Company Description

Phio Pharmaceuticals Corp. develops immuno-oncology therapeutics in the United States.

The company develops PH-762, INTASYL compound which reduces the expression of cell death Protein 1 (PD-1), a protein that inhibits T cells' ability to kill cancer cells; PH-894 that silences the BRD4, a protein which controls gene expression in both T cells and tumor cells, effecting the immune system as well as the tumor; and PH-804 that targets the TIGIT, a protein which inhibits the activity of Natural Killer cells.

The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018.

Phio Pharmaceuticals Corp. was incorporated in 2011 and is headquartered in Marlborough, Massachusetts.

Phio Pharmaceuticals Corp.
Phio Pharmaceuticals logo
Country United States
Industry Biotechnology
Sector Healthcare
Employees 9
CEO Robert J. Bitterman

Contact Details

Address:
257 Simarano Drive, Suite 101
Marlborough, Massachusetts 01752
United States
Phone (508) 767-3861
Website phiopharma.com

Stock Details

Ticker Symbol PHIO
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001533040
CUSIP Number 71880W303
ISIN Number US71880W4024
SIC Code 2834

Key Executives

Name Position
Robert J. Bitterman President, Chief Executive Officer and Chairman
Caitlin Kontulis Vice President of Finance and Administration and Secretary
Linda M. Mahoney Senior Vice President of Development

Latest SEC Filings

Date Type Title
Feb 6, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Jan 26, 2024 8-K Current Report
Dec 28, 2023 424B3 Prospectus
Dec 27, 2023 EFFECT Notice of Effectiveness
Dec 19, 2023 S-1 General form for registration of securities under the Securities Act of 1933
Dec 19, 2023 D Notice of Exempt Offering of Securities
Dec 8, 2023 8-K Current Report
Nov 9, 2023 8-K Current Report
Nov 9, 2023 10-Q Quarterly Report
Sep 29, 2023 S-8 Securities to be offered to employees in employee benefit plans